Serán BioScience has announced an expansion of its commercial manufacturing footprint with the development of a new 100,000-square-foot campus in Bend, Oregon. The advanced facility is designed to support pharmaceutical development and manufacturing projects for clients ranging from early-phase innovators to established commercial product companies, marking a significant milestone for the contract development and manufacturing organization (CDMO) sector.
Located in Bend’s growing bioscience corridor, the campus includes state-of-the-art laboratories, GMP manufacturing suites, and support areas aimed at boosting production capacity, scalability, and flexibility for complex drug products. Serán expects the new campus to enhance its capabilities in supporting sterile and non-sterile drugs, highly potent compounds, and diverse dosage form development.
According to company statements, the facility will allow Serán to advance its proprietary technologies and address increasing demand for CDMO services, particularly among specialty pharmaceutical and biotechnology clients requiring integrated development and manufacturing expertise. The site is designed to comply with global regulatory requirements, including FDA and EMA standards, supporting commercial manufacturing and clinical supply.
The Bend campus will create new jobs in the region and further strengthen Serán’s ability to address complex formulation and production challenges for advanced therapeutics. The facility is scheduled to become operational in 2026, with phased expansions planned to add additional manufacturing space and capabilities in response to market demand.